Hidradenitis Suppurativa

Tulisokibart met its HiSCR50 primary endpoint at 16 weeks in the phase 2b MK-7240-012 trial assessing moderate to severe hidradenitis suppurativa.

Raj Chovatiya, MD, PhD, discusses why 2-year BE HEARD EXT data support earlier systemic therapy discussions and where unmet needs remain for HS.

Pooled 2-year BE HEARD EXT data show shorter disease duration was linked with higher stringent response rates to bimekizumab in HS.

STOP-HS1 and STOP-HS2 data show povorcitinib nearly doubled treatment response rates versus placebo in moderate to severe HS.

This Q&A interview highlights key takeaways regarding hidradenitis suppurativa, raising awareness for HS Awareness week, and the current treatment landscape.

Findings suggest potential value in complete blood count (CBC)-derived parameters for assessments of hidradenitis suppurativa (HS) disease activity and severity.

54-week STOP-HS safety data for the JAK1-selective inhibitor povorcitinib showed no dose-dependent safety signal and few laboratory abnormalities.

54-week STOP-HS data show clinically meaningful improvements in pain, fatigue, and quality of life in one-third to two-thirds of patients.

Extension data through week 54 reveal deepening responses with povorcitinib in moderate-to-severe HS.

HS is associated with up to a nearly 2-fold increased risk of heart failure, coronary artery disease, myocardial infarction, venous thromboembolism, and all-cause mortality.

This phase 2b study on brensocatib did not meet its primary or secondary efficacy endpoints, causing Insmed to discontinue their HS program.

Extension data from BE HEARD showed that patients with shorter disease duration and lower baseline severity achieved higher response rates than those with longstanding, more severe disease.

Check out exclusive expert interviews of late breaking data from AAD 2026.

54-week data from the phase 3 STOP-HS1 and STOP-HS2 trials demonstrate JAK inhibitor povorcitinib's benefit in HS.

This interview highlights phase 3 findings on sonelokimab for individuals with hidradenitis suppurativa (HS).

This Q&A highlights Dr. Alexa B. Kimball's responses to questions on the FDA approval of secukinumab for pediatric patients with hidradenitis suppurativa (HS).

This FDA approval of secukinumab (Cosentyx) for hidradenitis suppurativa (HS) represents the fourth pediatric indication for the drug.

Bimekizumab was assessed using the International Hidradenitis Suppurativa Severity Score System (IHS4) outcomes in the BE HEARD I and II studies.

New data presented at EHSF in Malta boasts a reduced proportion of patients with severe HS at 3 years.

Catch up on some of the biggest alopecia areata news headlines covered by HCPLive from 2025 with this ‘Year in Review’ summary.

This study explored the potential impact of body mass index (BMI) and smoking on patients’ risk of developing hidradenitis suppurativa.

Explore the evolving role of AI in dermatology, balancing its benefits with concerns over accuracy, bias, and the human touch in patient care.

Investigators evaluated current prescription patterns for systemic HS medications among European HS specialists and opinions on criteria for biologic upgrades.

These new data indicate a potential lack of accuracy in hospital-based data on hidradenitis suppurativa (HS) outcomes among those in nonclinical settings.

This interview highlights long-term, phase 3 data from the SUNSHINE and SUNRISE core and extension trials on secukinumab for hidradenitis suppurativa.